It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Patients with Parkinson’s disease often complain of excessive daytime sleepiness which negatively impacts their quality of life. The pedunculopontine nucleus, proposed as a target for deep brain stimulation to improve freezing of gait in Parkinson’s disease, is also known to play a key role in the arousal system. Thus, the putative control of excessive daytime sleepiness by pedunculopontine nucleus area stimulation merits exploration for treating Parkinson’s disease patients. To this end, two adult nonhuman primates (macaca fascicularis) received a deep brain stimulation electrode implanted into the pedunculopontine nucleus area along with a polysomnographic equipment. Stimulation at low frequencies and high frequencies was studied, in healthy and then MPTP-treated nonhuman primates. Here, we observed that MPTP-treated nonhuman primates suffered from excessive daytime sleepiness and that low-frequency stimulation of the pedunculopontine nucleus area was effective in reducing daytime sleepiness. Indeed, low-frequency stimulation of the pedunculopontine nucleus area induced a significant increase in sleep onset latency, longer continuous periods of wakefulness and thus, a partially restored daytime wake architecture. These findings may contribute to the development of new therapeutic strategies in patients suffering from excessive daytime sleepiness.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Univ. Grenoble Alpes, CEA, LETI, Clinatec, Grenoble, France (GRID:grid.457348.9) (ISNI:0000 0004 0630 1517); Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France (GRID:grid.462307.4) (ISNI:0000 0004 0429 3736)
2 Univ. Grenoble Alpes, CEA, LETI, Clinatec, Grenoble, France (GRID:grid.457348.9) (ISNI:0000 0004 0630 1517); Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France (GRID:grid.462307.4) (ISNI:0000 0004 0429 3736); Univ. Grenoble Alpes, Inserm, Department of Neurosurgery, Grenoble, France (GRID:grid.7429.8) (ISNI:0000000121866389)
3 Yerkes National Primate Research Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University School of Medicine, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
4 Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France (GRID:grid.462307.4) (ISNI:0000 0004 0429 3736)
5 Emory University School of Medicine, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
6 Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France (GRID:grid.462307.4) (ISNI:0000 0004 0429 3736); Univ. Aix Marseille, Inserm, INS, Institut de Neurosciences des Systèmes, Marseille, France (GRID:grid.462494.9) (ISNI:0000 0004 0541 5643)
7 Univ. Grenoble Alpes, CEA, LETI, Clinatec, Grenoble, France (GRID:grid.457348.9) (ISNI:0000 0004 0630 1517)